ClinicalTrials.gg
CompletedNCT03361111BIOSAMOTUpdated Oct 11, 2019

BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment

An observational study in Severe Asthma, sponsored by Medical University of Warsaw. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-11.

Sponsored by Medical University of Warsaw · Observational

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
16
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 255 studies in Asthma with a site in Poland — 14 open to participants now, 22 under way, 7 of them phase 3. Asthma · Poland.

Enrollment
18th of 18
16 · median 240
Started
2013
with 18 others
Observational
18 of 255
3 open now
Registered
179th of 255
by date
Lead sponsor
9 of 255
Medical University of Warsaw

Among the 255 studies in Asthma with a site in Poland, this one is the 18th largest by enrollment of the 18 observational ones that give a count, is one of 19 that started in 2013, is one of 18 observational ones, and was the 179th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

14 of the 255 studies in Asthma with a site in Poland are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 255 studies in Asthma with a site in Poland, or all of them as a file.
02

Study summary

Eosinophil infiltration and degranulation in airways has been implicated in the pathology of asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the highly expressed genes in epithelial cells and lung fibroblasts in asthma. Omalizumab is approved as add-on therapy in the treatment of severe allergic asthma. The aim of the study is to assess inflammatory biomarkers including: blood and sputum eosinophilia, periostin and IL-6 as long-term clinical outcomes of omalizumab therapy.

Read the detailed description

Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with allergic severe asthma. In this observational study patients aged over 18 year with uncontrolled severe persistent asthma are selected for add-on therapy with omalizumab. Patients were on high dose of ICS and had a documented history of 2-6 exacerbations requiring treatment with systemic corticosteroids ( with >15 mg/day prednisone or other medications at similar dose, for at least 3 days). The individual dose and frequency of omalizumab administration is assessed from the dosing table. Lung function tests and asthma questionnaires (ACQ, AQLQ and RQLQ) are used in the aim of assessing clinical improvement after omalizumab treatment. Induced sputum (IS) and exhaled breath condensate (EBC) are used as a simple non-invasive methods for monitoring cellular and biochemical changes in the airways. Total blood eosinophil count, IS cytology, IS and EBC periostin and IL-6 concentrations are measured. Analyses are performed at entry and after 16, 52 and 104,156 weeks of omalizumab treatment.

03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • severe asthma
  • anti-IgE
  • periostin
  • induced sputum,
  • exhaled breath condensate
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Severe allergic asthma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. positive history of atopy
  2. serum total IgE level between 30 and 700 IU/ml
  3. body weight not more than 150 kg
  4. high dose of ICS and LABA
  5. a documented history of 2-6 exacerbations requiring treatment with systemic ( with >15 mg/day prednisone or other medications at similar dose, for at least 3 days).

Exclusion criteria

Exclusion Criteria:

  1. smoking
  2. pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
16 participants (actual)
Patient registry
No

This study also gives OmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in selected biomarkers in induced sputum

    eosinophil count

    Time frame: baseline and after 156 weeks of omalizumab treament

  2. Change in selected biomarkers in peripheral blood

    eosinophil count

    Time frame: baseline and after 156 weeks of omalizumab treament

  3. Change in selected biomarkers in induced sputum

    periostin

    Time frame: baseline and after 156 weeks of omalizumab treament

  4. Change in selected biomarkers in exhaled breath condensate

    periostin

    Time frame: baseline and after 156 weeks of omalizumab treament

  5. Change in selected biomarkers in induced sputum

    IL-6

    Time frame: baseline and after 156 weeks of omalizumab treament

  6. Change in selected biomarkers in exhaled breath condensate

    IL-6

    Time frame: baseline and after 156 weeks of omalizumab treament

Secondary outcomes

  1. Change in selected biomarkers in induced sputum

    eosinophils, periostin, IL-6

    Time frame: baseline and after at 16,52,104 weeks of omalizumab treament

  2. Change in selected biomarkers in exhaled breath condensate

    periostin, IL-6

    Time frame: baseline and after at 16, 52, 104 weeks of omalizumab treament

  3. Change in selected biomarkers in peripheral blood

    eosinophil count

    Time frame: baseline and after at 16, 52, 104 weeks of omalizumab treament

Other outcomes

  1. Lung function tests

    FEV1, FVC, FEV1/FVC

    Time frame: baseline and after at 16, 52, 104, 156 weeks of treament

07

Study locations

1 site
  • Joanna Hermanowicz-Salamon
    Warsaw, 00-707, Poland
08

References and documents

Publications

  • Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan;139(1):28-35. doi: 10.1378/chest.10-1194. Epub 2010 Aug 5. PubMed 20688929 ↗
  • Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. doi: 10.1164/rccm.201208-1414OC. PubMed 23471469 ↗
  • ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001 Sep 1;164(5):744-8. doi: 10.1164/ajrccm.164.5.2011026. PubMed 11549526 ↗
  • Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002 Nov 30;360(9347):1715-21. doi: 10.1016/S0140-6736(02)11679-5. PubMed 12480423 ↗
  • Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012 Sep;130(3):647-654.e10. doi: 10.1016/j.jaci.2012.06.025. Epub 2012 Aug 1. PubMed 22857879 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2013 to primary completion in Nov 2018, 67 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2017
First posted
Dec 4, 2017
StartActual
Apr 4, 2013
Primary completionActual
Nov 5, 2018
CompletionActual
Dec 30, 2018
Last update
Oct 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03361111
Responsible party
Joanna Hermanowicz-Salamon (MD PhD, Medical University of Warsaw) — Principal investigator
First posted
Dec 4, 2017
Start date
Apr 4, 2013
Primary completion
Nov 5, 2018
Completion
Dec 30, 2018
Last update
Oct 11, 2019

Study contacts

Joanna Hermanowicz-Salamon, MD,PhD
principal investigator · Department of Internal Medicine, Pulmonary Diseases and Allergy Medical University of Warsaw, Poland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion